Evidence map›Paper›PMID 33272243›Full record

ArticleBMC cancer2020

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors.

Clémentine Bouchez, Johan Pluvy, Ghassen Soussi, Marina Nguenang, Solenn Brosseau, Morgan Tourne, Mégane Collin, Nathalie Théou-Anton, Alice Guyard, Jamila Ammar and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Spontaneous regression of choroidal metastasis from renal cell carcinoma.American journal of ophthalmology case reports · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Clémentine BouchezThoracic Oncology Department & CIC1425-CLIP2 Early Phase Cancer Clinical Trials Unit, University Hospital Bichat-Claude Bernard, Medical Faculty, Université de Paris, Hôpital Bichat, APHP, 46 Rue Henri Huchard, 75018, Paris, France.
Johan PluvyThoracic Oncology Department & CIC1425-CLIP2 Early Phase Cancer Clinical Trials Unit, University Hospital Bichat-Claude Bernard, Medical Faculty, Université de Paris, Hôpital Bichat, APHP, 46 Rue Henri Huchard, 75018, Paris, France.
Ghassen SoussiThoracic Oncology Department & CIC1425-CLIP2 Early Phase Cancer Clinical Trials Unit, University Hospital Bichat-Claude Bernard, Medical Faculty, Université de Paris, Hôpital Bichat, APHP, 46 Rue Henri Huchard, 75018, Paris, France.
Marina NguenangThoracic Oncology Department & CIC1425-CLIP2 Early Phase Cancer Clinical Trials Unit, University Hospital Bichat-Claude Bernard, Medical Faculty, Université de Paris, Hôpital Bichat, APHP, 46 Rue Henri Huchard, 75018, Paris, France.
Solenn BrosseauThoracic Oncology Department & CIC1425-CLIP2 Early Phase Cancer Clinical Trials Unit, University Hospital Bichat-Claude Bernard, Medical Faculty, Université de Paris, Hôpital Bichat, APHP, 46 Rue Henri Huchard, 75018, Paris, France.
Morgan TourneDepartment of Genetics, University Hospital Bichat-Claude Bernard, Medical Faculty, Université de Paris, Paris, France.
Mégane CollinRadiology Department, University Hospital Bichat-Claude Bernard, Medical Faculty, Université de Paris, Paris, France.
Nathalie Théou-AntonDepartment of Genetics, University Hospital Bichat-Claude Bernard, Medical Faculty, Université de Paris, Paris, France.
Alice GuyardDepartment of Pathology, University Hospital Bichat-Claude Bernard, Medical Faculty, Université de Paris, Paris, France.
Jamila AmmarDepartment of Ophtalmology, University Hospital Bichat-Claude Bernard, Medical Faculty, Université de Paris, Paris, France.
Antoine KhalilRadiology Department, University Hospital Bichat-Claude Bernard, Medical Faculty, Université de Paris, Paris, France.
Gérard ZalcmanThoracic Oncology Department & CIC1425-CLIP2 Early Phase Cancer Clinical Trials Unit, University Hospital Bichat-Claude Bernard, Medical Faculty, Université de Paris, Hôpital Bichat, APHP, 46 Rue Henri Huchard, 75018, Paris, France.
Valérie GounantThoracic Oncology Department & CIC1425-CLIP2 Early Phase Cancer Clinical Trials Unit, University Hospital Bichat-Claude Bernard, Medical Faculty, Université de Paris, Hôpital Bichat, APHP, 46 Rue Henri Huchard, 75018, Paris, France. valerie.gounant@aphp.fr.
Hôpital Bichat-Claude-Bernard · FRUniversité Claude Bernard Lyon 1 · FRUniversité Paris Cité · FRAssistance Publique – Hôpitaux de Paris · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChoroidal metastases are the most common eye metastatic site. The prevalence of choroidal metastases in NSCLC patients has been reported to vary from 0.2 to 7% in historical series. Although previously reported, little is known about choroidal metastasis in Epidermal Growth Factor Receptor (EGFR)-mutant Non-small cell lung cancer (NSCLC). This study sought to describe the prevalence of choroidal metastases among patients with EGFR-mutated NSCLC and their characteristics, and to estimate their impact on prognosis.

methodsWe conducted a single-center retrospective study including all consecutive metastatic EGFR-mutant NSCLC patients, from Sept. 2015 to Oct. 2018. The EGFR-mutant NSCLC patients were identified via the Department of Genetics' files. Patients who exhibited choroidal metastases were compared to patients without choroidal metastases. Kaplan-Meier analysis and log-rank test were conducted to assess median overall survival (OS) from diagnosis for the two groups. The study was approved by the IRB as CEPRO number #2020-010.

resultsPrevalence of choroidal metastases in EGFR-mutated NSCLCs was 8.4% (7/83). Five were women, and four current or former smokers. Molecular analysis showed three tumors with exon 19 deletion, three with L858R mutation, and one with complex exon 21 mutation. The choroidal metastases were symptomatic in six/seven patients. Visual disturbances decreased in all but one symptomatic cases upon EGFR TKI, and the choroidal response was maintained over time. Median follow-up was 42.2 mo (95%CI [37.2-47.1]). Median OS in the choroidal metastasis group was 23.4 mo (95%CI [0.1-51.4]) versus 27.9 mo (95%CI [16.9-38.9]) in the non-choroidal metastasis group (p = 0.32). In the choroidal metastasis group, 2-year and 5-year OS were 47.6 and 0%, respectively, versus 55.8 and 26.3% in the non-choroidal metastasis subset.

conclusionsChoroidal metastases in NSCLC EGFR-mutant patients are rare but should be systematically suspected in case of visual disturbance. TKIs are efficient for treating visual symptoms. Whether choroidal metastases confer a worse prognosis remains unclear owing to the third-generation EGFR TKI osimertinib first-line registration.

Indexed as

Carcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasm MetastasisProtein Kinase InhibitorsRetrospective StudiesTreatment OutcomeProtein Kinase InhibitorsChoroidal metastasesEGFR mutationLung cancerNSCLCTargeted therapyTyrosine kinase inhibitors

Identifiers

PMID33272243
PMCPMC7712981
OpenAlexW3106843536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.